Table 2

Baseline characteristics of HIV infection of patients included in the ANRS CO 13 HEPAVIH cohort of HIV-HCV co-infected patients, France, 2006-2008

Total N=1175

HCV chronically infected patients N=1048

Sustained HCV responders N=127


CDC clinical stage: C, N (%)

324 (27.8)

300 (28.9)

24 (19.2)

Years since HIV diagnosis, median (IQR)

18 (13-20)

18 (13-20)

18 (14-21)

HIV transmission category, N (%)

Intravenous drug use

724 (62.0)

651 (62.5)

73 (57.9)

Sexual

318 (27.2)

282 (27.1)

36 (28.6)

Transfusion

85 (7.3)

73 (7.0)

12 (9.5)

Other or unknown

40 (3.4)

35 (3.4)

5 (4.0)

Nadir CD4 (/μl), median (IQR)

150 (66-248)

146 (65-247)

169 (96-251)

CD4 cells count at initiation of antiretroviral treatment (/μl), median (IQR)

242 (139-357)

240 (132-354)

256 (191-396)

CD4 cells count at baseline (/μl), median (IQR)

442 (304-633)

438 (300-630)

492 (345-662)

CD4 cells count at baseline (/μl), N (%)

<200

130 (11.2)

126 (12.2)

4 (3.1)

200-350

251 (21.6)

223 (21.6)

28 (22.0)

351-500

301 (25.9)

269 (26.1)

32 (25.2)

>500

479 (41.3)

416 (40.2)

63 (49.6)

Patients with <40 HIV RNA copies/ml, N (%)

797 (68.8)

702 (68.1)

95 (74.8)

Patients receiving HAART, N (%)

841 (71.6)

750 (71.6)

91 (71.6)

2 NRTI + 1 PI

613 (52.2)

552 (52.7)

61 (48.0)

2 NRTI + 1 NNRTI

183 (15.6)

158 (15.1)

25 (19.7)

1 NRTI + 1 NNRTI + 1 PI

45 (3.8)

40 (3.8)

5 (3.9)

Regimen including raltegravir

26 (2.2)

23 (2.2)

3 (2.4)


PI: protease inhibitor; NRTI: nucleoside reverse transcriptase inhibitor; NNRTI: non-nucleoside reverse transcriptase inhibitor; IQR: interquartile range;HAART: highly active antiretroviral therapy

Loko et al. BMC Infectious Diseases 2010 10:303   doi:10.1186/1471-2334-10-303

Open Data